4.6 Article

Qualitative and quantitative evaluation of a new wearable device for ECG and respiratory Holter monitoring

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 272, Issue -, Pages 231-237

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2018.06.044

Keywords

ECG monitoring; Respiratory monitoring, wearable device; Apnea

Ask authors/readers for more resources

Background: Recent advances in wearable technology make continuous cardiorespiratory monitoring possible, with potential applications in assessment of cardiopulmonary patients, healthy subjects and athletes. The aim of the present study was to qualitatively and quantitatively evaluate a new wearable device (Learn Inspire Free Entertain = L.I.F.E.) by embedding in a compression shirt a 12-lead ECG system and 5 respiratory sensors. Methods: Thirty cardiorespiratory patients and ten healthy subjects were studied for 24 h during their usual life activities. In 8 healthy subjects, simultaneous measurements of the device and of an ergo-spirometer were performed during different levels of ventilation in five different body positions. The quality of ECG signals in terms of measurability of heart rate, P wave, QRS complex and ST segment, was analyzed by four expert cardiologists/ respiratory physiologists using an arbitrary 1-5 scale. The sum of the respiratory signals was used to calculate the respiratory rate, inspiratory time and relative changes of tidal volume. These parameters were compared to ergo-spirometer measurements. Results: Median quality value was >3 for heart rate, QRS complex, ST segment and P wave (except in L3, aVL, aVF, V1 and V2 leads). Median quality of respiratory traces was >4 in patients and between 3 and 4 in healthy subjects. The respiratory monitoring of respiratory rate and inspiratory time was accurate in all body positions. Tidal volumes were underestimated due to a high level of ventilation. Conclusions: The L.I.F.E. device provides an accurate continuous monitoring of cardiorespiratory signals during the 24 h both in normal subjects and cardiorespiratory patients. (C) 2018 Elsevier B.V. All right reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rehabilitation

Volumes da parede toracica, mobilidade diafragmatica e capacidade funcional em pacientes com mucopolissacaridoses

Barbara Bernardo Figueiredo, Cyda Reinaux, Helen Fuzari, Antonio Sarmento, Juliana Fernandes, Armele Dornelas de Andrade

Summary: This study investigated various physiological indicators of MPS patients and compared them with healthy individuals. The results showed significant reductions in body composition, lung function, respiratory muscle strength, and functional capacity among MPS patients.

DISABILITY AND REHABILITATION (2023)

Article Cardiac & Cardiovascular Systems

Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base

Federica Toto, Elisabetta Salvioni, Damiano Magri, Susanna Sciomer, Massimo Piepoli, Roberto Badagliacca, Arianna Galotta, Nikita Baracchini, Stefania Paolillo, Ugo Corra, Rosa Raimondo, Rocco Lagioia, Pasquale Perrone Filardi, Annamaria Iorio, Michele Senni, Michele Correale, Mariantonietta Cicoira, Enrico Perna, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Gianfranco Sinagra, Gianfranco Parati, Gaia Cattadori, Francesco Bandera, Maurizio Bussotti, Massimo Mapelli, Manlio Cipriani, Alice Bonomi, Goncalo Cunha, Federica Re, Carlo Vignati, Andrea Garascia, Carlo Lombardi, Angela B. Scardovi, Andrea Passantino, Michele Emdin, Claudio Passino, Caterina Santolamazza, Davide Girola, Denise Zaffalon, Dario Vizza, Fabiana De Martino, Piergiuseppe Agostoni

Summary: This study aimed to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF patients and found that it does not influence patients' outcome.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

Editorial Material Medicine, General & Internal

A heart twice as big as normal

Massimo Mapelli

CANADIAN MEDICAL ASSOCIATION JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i

Massimo Mapelli, Valentina Mantegazza, Cristina Ferrari, Roberto Cimino, Riccardo Maragna, Gianluca Pontone, Mauro Pepi, Piergiuseppe Agostoni

Summary: This case report presents a dramatic reversal of remodeling and regression of disease in a young woman with HFrEF on hemodialysis treated with sacubitril/valsartan and SGLT2i. After 10 months of follow-up, the patient showed normalization of left ventricular and atrial volumes and improved ejection fraction within the normal range. Cardiac biomarkers and exercise performance also improved simultaneously. The hemodialysis protocol and loop diuretic dose remained unchanged throughout.

ESC HEART FAILURE (2023)

Article Biochemistry & Molecular Biology

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure

Maura Brioschi, Yuri D'Alessandra, Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, Sonia Eligini, Alice Mallia, Veronica Ricci, Erica Gianazza, Stefania Ghilardi, Piergiuseppe Agostoni, Cristina Banfi

Summary: Sacubitril/Valsartan, a combination drug for heart failure treatment, reduces the levels of miR-29b-3p, miR-221-3p, and miR-503-5p in the plasma of patients with stable HF. These miRNAs have potential roles in HFrEF pathophysiology.

BIOMEDICINES (2023)

Editorial Material Pediatrics

Editorial: An International Journey into the Research Progress of Pediatric Cardiology

Massimo Mapelli, Paola Zagni

CHILDREN-BASEL (2023)

Article Pharmacology & Pharmacy

Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration

Massimo Mapelli, Irene Mattavelli, Stefania Paolillo, Elisabetta Salvioni, Damiano Magri, Arianna Galotta, Fabiana De Martino, Valentina Mantegazza, Carlo Vignati, Immacolata Esposito, Simona Dell'Aversana, Roberta Paolillo, Teresa Capovilla, Gloria Tamborini, Alessandro Alberto Nepitella, Pasquale Perrone Filardi, Piergiuseppe Agostoni

Summary: Our study aimed to evaluate the effects of different doses of sacubitril/valsartan on exercise parameters, echocardiographic changes, and biomarker levels. The results showed that sacubitril/valsartan improved functional capacity, induced left ventricle reverse remodeling, reduced NT-proBNP levels, and improved quality of life.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Heart failure patients with improved ejection fraction: Insights from the MECKI score database

Piergiuseppe Agostoni, Francesca Romana Pluchinotta, Elisabetta Salvioni, Massimo Mapelli, Arianna Galotta, Alice Bonomi, Damiano Magri, Enrico Perna, Stefania Paolillo, Ugo Corra, Rosa Raimondo, Rocco Lagioia, Roberto Badagliacca, Pasquale Perrone Filardi, Anna Apostolo, Michele Senni, Annamaria Iorio, Michele Correale, Jeness Campodonico, Pietro Palermo, Mariantonietta Cicoira, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Mauro Contini, Beatrice Pezzuto, Gianfranco Sinagra, Gianfranco Parati, Gaia Cattadori, Cosimo Carriere, Marco Cittar, Maria Vittoria Matassini, Andrea Salzano, Antonio Cittadini, Marco Mase, Francesco Bandera, Maurizio Bussotti, Irene Mattavelli, Federica Re, Carlo Vignati, Carlo Lombardi, Angela B. Scardovi, Susanna Sciomer, Andrea Passantino, Michele Emdin, Andrea Di Lenarda, Claudio Passino, Caterina Santolamazza, Federica Moscucci, Denise Zaffalon, Massimo Piepoli, MECKI Score Res Grp

Summary: The study found that heart failure patients with improved ejection fraction have distinct clinical characteristics, biology, and prognosis compared to patients with persistently reduced ejection fraction. Despite having milder symptoms, HFimpEF patients still face risks of adverse outcomes.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Letter Cardiac & Cardiovascular Systems

Differences between heart failure specialists and non-specialists regarding heart failure drug implementation and up-titration

Charles Fauvel, Clara Ines Saldarriaga Giraldo, Anders Barassa, Anastasia Shchendrygina, Massimo Mapelli, Nina Jakus, Antoine Jobbe-Duval, Anja Zupan Meznar, Brahim Harbaoui, Emmanuelle Berthelot, Francois Roubille, Giuseppe Rosano, Nathan Mewton

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Physiology of exercise and heart failure treatments: cardiopulmonary exercise testing as a tool for choosing the optimal therapeutic strategy

Jeness Campodonico, Mauro Contini, Marina Alimento, Massimo Mapelli, Elisabetta Salvioni, Irene Mattavelli, Alice Bonomi, Piergiuseppe Agostoni

Summary: The pharmacological treatment of heart failure has become more complex in recent decades due to the availability of new effective drugs. This study aims to evaluate the effects of different drugs on cardiopulmonary function in patients with heart failure, both at rest and during exercise, in order to guide the choice of appropriate treatment protocols for individual patients and promote precision medicine.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Activities of daily living in heart failure patients and healthy subjects: when the cardiopulmonary assessment goes beyond traditional exercise test protocols

Massimo Mapelli, Elisabetta Salvioni, Irene Mattavelli, Paola Gugliandolo, Alice Bonomi, Pietro Palermo, Maddalena Rossi, Davide Stolfo, Finn Gustafsson, Massimo Piepoli, Piergiuseppe Agostoni

Summary: Heart failure patients often experience dyspnea during daily activities that may represent maximal or supramaximal exercises for them. New-generation portable metabolimeters can measure task-related oxygen intake in different scenarios. By studying the metabolic behaviors of heart failure patients and healthy subjects during activities of daily living (ADLs), we can better understand the relationship between metabolic variables and CPET parameters.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

What about chronotropic incompetence in heart failure with mildly reduced ejection fraction? Clinical and prognostic implications from the Metabolic Exercise combined with Cardiac and Kidney Indexes score dataset

Damiano Magri, Giovanna Gallo, Massimo Piepoli, Elisabetta Salvioni, Massimo Mapelli, Carlo Vignati, Emiliano Fiori, Melwyn Luis Muthukkattil, Ugo Corra, Marco Metra, Stefania Paolillo, Antonello Maruotti, Pierfrancesco Alaimo Di Loro, Michele Senni, Rocco Lagioia, Domenico Scrutinio, Michele Emdin, Claudio Passino, Gianfranco Parati, Gianfranco Sinagra, Michele Correale, Roberto Badagliacca, Susanna Sciomer, Andrea Di Lenarda, Piergiuseppe Agostoni, Pasquale Perrone Filardi

Summary: This study found an association between chronotropic incompetence, exercise capacity, and cardiovascular death risk in patients with HFmrEF. Larger prospective studies are needed to determine the potential use of chronotropic incompetence in HFmrEF management.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

The cardiopulmonary exercise test in the prognostic evaluation of patients with heart failure and cardiomyopathies: the long history of making a one-size-fits-all suit

Elisabetta Salvioni, Alice Bonomi, Damiano Magri, Marco Merlo, Beatrice Pezzuto, Mattia Chiesa, Massimo Mapelli, Nikita Baracchini, Gianfranco Sinagra, Massimo Piepoli, Piergiuseppe Agostoni

Summary: Cardiopulmonary exercise tests (CPET) are crucial for evaluating the functional capacity of chronic heart failure (HF) patients. The MECKI score, developed by a group of Italian centers skilled in HF management and CPET analysis, has been extensively validated and shown to be effective in risk stratification for HF. The MECKI score research group has grown over time and is now investigating other areas such as cardiomyopathy.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Exercise in hypoxia: a model from laboratory to on-field studies

Carlo Vignati, Mauro Contini, Elisabetta Salvioni, Carolina Lombardi, Sergio Caravita, Grzegorz Bilo, Erik R. Swenson, Gianfranco Parati, Piergiuseppe Agostoni

Summary: Patients with chronic heart failure may safely spend time at altitudes <3500 m, but may experience decreased exercise capacity proportional to the severity of heart failure and altitude. Specialized 'hypoxic-tailored treatment' is necessary to avoid pharmacological interference with altitude adaptation mechanisms.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Beyond VO2: the complex cardiopulmonary exercise test

Irene Mattavelli, Carlo Vignati, Stefania Farina, Anna Apostolo, Gaia Cattadori, Fabiana De Martino, Beatrice Pezzuto, Denise Zaffalon, Piergiuseppe Agostoni

Summary: Cardiopulmonary exercise test (CPET) is a valuable diagnostic tool in heart failure (HF) due to its strong prognostic value. The peak oxygen uptake (peak VO2) is the most important parameter provided by CPET, indicating the maximum rate of oxygen consumption during physical exertion. However, standard CPET cannot distinguish between impairments in oxygen delivery or extraction, necessitating the use of more complex technologies.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

No Data Available